Background-There is a paucity of data reporting the clinical outcomes of biodegradable polymer biolimus-eluting stent (BP-BES) compared with durable polymer everolimus-eluting stent (DP-EES) beyond 1 year after stent implantation when the polymer is fully degraded. Methods and Results-The NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-Eluting Stent Trial (NEXT) is a prospective, multicenter, randomized, open-label, noninferiority trial comparing BP-BES with DP-EES in patients scheduled for percutaneous coronary intervention using drug-eluting stent (DES) without any exclusion criteria among 98 participating centers in Japan. The trial was designed to evaluate noninferiority of BP-BES relative to DP-EES in terms of any targetlesion revascularization at 1 year and death or myocardial infarction at 3 years. Between May and October 2011, 3235 patients were randomly assigned to receive either BP-BES (1617 patients) or DP-EES (1618 patients). Complete 3-year follow-up was achieved in 97.6% of patients. At 3 years, the primary safety end point of death or myocardial infarction occurred in 159 patients (9.9%) in the BP-BES group and in 166 patients (10.3%) in the DP-EES group, demonstrating noninferiority of BP-BES relative to DP-EES (P noninferiority<0.0001 and P superiority=0.7). Cumulative incidence of target-lesion revascularization was not significantly different between the 2 groups (7.4% versus 7.1%; P=0.8). By a landmark analysis at 1 year, the cumulative incidences of death or myocardial infarction and target-lesion revascularization were also not significantly different between the 2 groups (4.6% versus 5.2%; P=0.46 and 3.3% versus 2.7%; P=0.39, respectively). Conclusions-Safety and efficacy outcomes of BP-BES were non inferior to those of DP-EES 3 years after stent implantation. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01303640. The sponsor of this study contributed to the study design, but had no involvement in data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. 1,2 Pathological studies have suggested that inflammatory reactions against durable polymer (DP) coated on the stent and neoatherosclerosis formation are substrates for these dramatic late events. 3 DES using biodegradable polymer (BP) were designed to overcome the long-term adverse vascular reactions related to the DP. In the Limus Eluted From A Durable Versus ERodable Stent Coating (LEADERS) trial, the rate of very late ST was significantly lower after implantation of BP biolimus-eluting stents (BES) compared with first-generation DP sirolimuseluting stents (SES). 4 Furthermore, in a pooled analysis of 3 trials (ISAR-TEST 3, ISAR-TEST 4, and LEADERS), the risk of TLR as well as ST at 4 years was significantly reduced with BP DES compared with DP-SES. [4][5][6] [7] The risk reduction in ST was mainly driven by the reduction of very late ST beyond 1 year after stent implantation. However, SES is no longer used in the current clinical practice, and a second-generation biocompatible DP DES would be a more clinically relevant comparator stent for a BP DES.
Natsuaki et al Biodegradable or Durable Polymer Coronary Stent
L ate adverse events such as very late stent thrombosis (ST) and late target-lesion revascularization (TLR) occurring beyond 1 year have emerged as new enemies after first-generation drug-eluting stents (DES) implantation. 1, 2 Pathological studies have suggested that inflammatory reactions against durable polymer (DP) coated on the stent and neoatherosclerosis formation are substrates for these dramatic late events. 3 DES using biodegradable polymer (BP) were designed to overcome the long-term adverse vascular reactions related to the DP. In the Limus Eluted From A Durable Versus ERodable Stent Coating (LEADERS) trial, the rate of very late ST was significantly lower after implantation of BP biolimus-eluting stents (BES) compared with first-generation DP sirolimuseluting stents (SES). 4 Furthermore, in a pooled analysis of 3 trials (ISAR-TEST 3, ISAR-TEST 4, and LEADERS), the risk of TLR as well as ST at 4 years was significantly reduced with BP DES compared with DP-SES. [4] [5] [6] [7] The risk reduction in ST was mainly driven by the reduction of very late ST beyond 1 year after stent implantation. However, SES is no longer used in the current clinical practice, and a second-generation biocompatible DP DES would be a more clinically relevant comparator stent for a BP DES.
The NOBORI Biolimus-Eluting Versus XIENCE/ PROMUS Everolimus-Eluting Stent Trial (NEXT) is the largest prospective multicenter randomized trial comparing BP-BES with second-generation biocompatible DP everolimus-eluting stent (EES). 8 Nobori BP-BES is a stainless steel alloy stent with relatively thick strut (120 μm) using an abluminally coated BP (poly-lactic acid) eluting biolimus A9, a highly lipophilic analog of sirolimus. Nobori BP-BES provides a small initial burst and sustained simultaneous drug release with polymer degradation taking place during a period of 6 to 9 months. In an animal study, BP-BES was reported to show better histopathologic characteristics with less intimal hyperplasia and reduced inflammatory reaction as compared with DP-EES. 9 In both the NEXT and the COMPARE-2 trials, BP-BES was demonstrated to be noninferior to DP-EES in the efficacy and safety outcomes at 1 year. 8, 10 In the NEXT and Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II) trials, 11, 12 BP-BES could not demonstrate better safety over DP-EES beyond 1 year ≤2 years after stent implantation, although the advantages of coronary stent using BP could potentially emerge beyond 1 year after stent implantation when polymer has been fully degraded. However, 2-year follow-up might be too short for BP-BES to demonstrate long-term benefits over DP-EES because of the long duration of polymer degradation. Therefore, we report final 3-year clinical outcomes from the NEXT study.
Methods

Study Design and Patients
As previously described in detail, the NEXT is a prospective, multicenter, randomized, assessor-blind, noninferiority trial comparing BP-BES with DP-EES in Japan. 8, 11 Patients scheduled for percutaneous coronary intervention (PCI) using DES among 98 participating centers (List A in the Appendix in the Data Supplement) were to be enrolled without any exclusion criteria.
The study protocol was approved by the Institutional Review Board at each participating center. Written informed consent was obtained from all the study patients. The study was registered at the ClinicalTrials.gov (NCT01303640).
Randomization
Patients were randomly assigned to undergo PCI with either BP-BES or DP-EES. Randomization was performed in a 1:1 ratio by a webbased allocation system and was stratified by center, diabetic status, and participation in the imaging substudies (angiography, intravascular ultrasound, optical coherence tomography, and coronary endothelial function). The study-group assignments were blinded to the statistician, members of the independent clinical events committee, steering committee, clinical research organization (Research Institute for Production Development, Kyoto, Japan), angiographic core laboratory (Cardiocore, Tokyo, Japan), and the sponsor (Terumo Japan; List B in the Appendix in the Data Supplement). The principal investigator and the steering committee members designed the study in collaboration with the sponsor.
Procedures
Details of the study procedures are described in the Methods in the Data Supplement. Baseline and follow-up data were reported not by the physicians, but by the dedicated clinical research coordinators belonging to the participating centers (2332 patients), to local site management organizations (431 patients) or to the clinical research organization (472 patients). The independent clinical research coordinators belonging to the same clinical research organization checked the quality of baseline data in 602 patients (19%) in whom data entry was conducted by the site investigators or local site management organizations. Most of the follow-up information was obtained from the outpatient hospital chart, although the patients were not fully monitored. For patients without hospital visits, the follow-up information was collected by the mail questionnaire to the patients or by telephone call to the referring physicians. Inconsistencies about reports on the follow-up events were resolved by queries to the site investigators. All the primary end point events were adjudicated by the independent clinical event committee based on the original source documents. For the patients with target-vessel revascularization (TVR), angiograms
WHAT IS KNOWN
• Equivalent 1-year outcomes of biodegradable polymer biolimus-eluting stent as compared with durable polymer everolimus-eluting stent are previously reported.
• However, there is a paucity of data reporting the clinical outcomes beyond 1 year after biodegradable polymer biolimus-eluting stent implantation as compared with durable polymer everolimus-eluting stent implantation, when the advantages of coronary stent using biodegradable polymer could emerge because of the complete polymer degradation.
WHAT THE STUDY ADDS
• Clinical outcome after biodegradable polymer biolimus-eluting stent implantation was not different from that after durable polymer everolimus-eluting stent implantation through 3 years and beyond 1 year after stent implantation.
• We observed no difference in clinical outcomes with biodegradable polymer biolimus-eluting stent compared with durable polymer everolimus-eluting stent. Biodegradable or Durable Polymer Coronary Stent were analyzed by the angiographic core laboratory to distinguish TLR from TVR other than TLR.
Procedural anticoagulation was achieved with unfractionated heparin following the local site protocols. The recommended antiplatelet regimen included aspirin (≥81 mg daily) indefinitely and thienopyridines (75-mg clopidogrel or 200-mg ticlopidine daily) for at least 3 months. The duration of the dual antiplatelet therapy was left to the discretion of each attending physician. The status of antiplatelet therapy was evaluated throughout the follow-up period. Discontinuation of thienopyridines and aspirin was defined to be persistent when withdrawn for >2 months.
1 Discontinuation of dual antiplatelet therapy was defined as persistent discontinuation of either thienopyridines or aspirin.
The primary efficacy end point was any TLR at 1 year, whereas the primary safety end point was a composite of death or myocardial infarction (MI) at 3 years. Other prespecified outcome measures included clinically driven TLR, TVR, any coronary revascularization, all-cause death, cardiac death, MI, ST, hospitalization for heart failure, stroke, bleeding, a device-oriented composite (cardiac death, target-vessel MI, and TLR), a patient-oriented composite (all-cause death, MI, and any repeat coronary revascularization), target-lesion failure (TLF: cardiac death, target-vessel MI, or ischemia-driven TLR), target-vessel failure (TVF: cardiac death, MI, or ischemiadriven TVR), and major adverse cardiac events (MACE: cardiac death, MI, or ischemia-driven TLR). Definitions are described in detail in the Methods in the Data Supplement.
Statistical Analysis
Categorical variables were presented as number and percentage and were compared with the χ 2 test. Continuous variables were expressed as mean value±SD or median with interquartile range. Continuous variables were compared using the Student t test or Wilcoxon rank sum test based on their distributions.
The trial was a noninferiority trial, which was powered for evaluating noninferiority of BP-BES to DP-EES on the primary efficacy end point at 1 year. At study initiation, the estimated TLR rate of DP-EES was not available in Japan. Therefore, assuming that TLR rate is equivalent to that of SES, we adopted the same sample size calculation as used in the Randomized Evaluation of Sirolimus-Eluting Versus Everolimus-Eluting Stent Trial (RESET), which subsequently demonstrated noninferiority of DP-EES relative to SES in terms of both TLR rate and in-segment late loss. 13 With the assumption of 6.9%, TLR rate based on the data from the j-Cypher registry, 14 a total of 3000 patients would yield 95% power to detect noninferiority with a noninferiority margin of 3.4% (half of the 6.9%) at a level of 1-sided type 1 error of 0.025. A total of 3200 patients were to be enrolled considering possible dropout during follow-up. We confirmed the calculated sample size was enough to attest the noninferiority of BP-BES to DP-EES on the coprimary end point for the safety of this study, a composite end point of death/MI through 3 years follow-up. In j-Cypher study, the death/MI rate through 3 years was 11.2% in the 10 778 subjects who received SES only. The true rate in this study was assumed as 12.2% for both treatment arms because occurrence of MI is expected to be higher because of the use of the Academic Research Consortium (ARC) definitions. The calculated 3000 patients would yield 91% power for the coprimary end point with a noninferiority margin of 4.3% at a level of 1-sided type 1 error of 0.025. The noninferiority margin for the efficacy end point was set as 50% of the true rate, whereas the noninferiority margin for the safety end point was set as 35% of the true rate, considering the need for more stringent noninferiority margin for evaluating the safety.
Clinical outcomes were analyzed according to intention-to-treat principle. Each end point was assessed by the Kaplan-Meier method and compared by the log-rank test. Effect of treatment was compared by the Cox proportional hazard model and it was expressed by hazard ratio with 95% confidence interval. Clinical follow-up at 3 years was regarded to be achieved with an allowance of 2 months (at least 1035 days follow-up). As a subgroup analysis, treatment effect of BP-BES relative to DP-EES was evaluated in several prespecified subgroups including those patients with diabetes mellitus, insulin-treated diabetes mellitus , elderly, hemodialysis, and multivessel PCI. In the prespecified subgroup analysis, we also conducted the formal interaction test between the stent type and the subgroup factors. Clinical outcomes between 1 and 3 years were evaluated by using the landmark analysis method in which we set the 1-year landmark point. 15 All statistical analyses were performed by a physician (M.N.) and a statistician (T.M.) with the use of JMP 10 (SAS Institute Inc, Cary, NC) software and SAS 9.4 (SAS Institute Inc). All reported P values were 2-sided and P<0.05 were regarded as statistically significant except for the noninferiority testing. One-sided P<0.025 was considered statistically significant to attest noninferiority. 
Results
Between May and October 2011, a total of 3241 patients (35%) were enrolled in the trial among 9342 patients who underwent PCI using DES in the participating centers during the enrollment period. Excluding 6 patients who withdrew consent, 3235 patients with 4069 lesions were randomly assigned to receive either BP-BES (1617 patients) or DP-EES (1618 patients; Figure 1) .
The study population included large proportions of patients with advanced age, diabetes mellitus, multivessel coronary artery disease, and previous PCI, and significant proportions of patients with heart failure, hemodialysis, left main coronary artery disease, small vessel disease, chronic total occlusion, and bifurcation lesions, whereas the prevalence of patients with acute MI and high Synergy Between PCI With Taxus and Cardiac Surgery (SYNTAX) score was low. The 2 groups of patients were generally well balanced in terms of baseline clinical and lesion characteristics (Table 1) .
Complete 3-year follow-up was achieved in 3158 patients (97.6%; Figure 1 ). The cumulative incidence of persistent discontinuation of dual antiplatelet therapy was not significantly different between the BP-BES and the DP-EES groups (13.8% versus 13.0% at 1 year and 43.7% versus 42.6% at 3 years; P=0.46; Figure 2) .
The primary end point of death/MI occurred in 159 patients (9.9%) in the BP-BES group and in 166 patients Figure 3) . The difference in the rate of death/MI between the BP-BES and the DP-EES groups was −0.44% (upper: 97.5% confidence interval, 2.2%), demonstrating noninferiority of BP-BES to DP-EES in terms of death/MI with a noninferiority margin of 4.3% (P noninferiority<0.0001).
Testing for superiority was not statistically significant (P superiority=0.7). About the efficacy end point of TLR, the angiographic core laboratory evaluated the angiograms at the time of events in 223 of 228 first TLR events (97.8%) and in 320 of 332 first TVR events (96.4%). The cumulative 3-year incidence of any TLR was not significantly different between the BP-BES and the DP-EES groups (7.4% versus 7.1%; P=0.8; Table 2 ; Figure 3 ). Cumulative incidences of TVR and clinically driven TLR were also not significantly different between the BP-BES and the DP-EES groups (Table 2) .
A sensitivity analysis was conducted in 1959 lesions exclusively treated with BP-BES and 1927 lesions with DP-EES. Cumulative incidence of lesion-based TLR among lesions treated exclusively with the study stents was not different between the BP-BES and the DP-EES groups (7.8% versus 7.7%; P=0.89; Table I in the Data Supplement).
The cumulative 3-year incidences of the prespecified combined end points including a device-oriented composite, a patient-oriented composite, TLF, TVF, and MACE were also not significantly different between the 2 groups ( Table 2) .
Between 1 and 3 years, the cumulative incidence of death/ MI was not different between the 2 groups (4.6% versus 5.2%; P=0.46; Table 3; Figure 4 ). The cumulative incidences of both definite very late ST and late TLR beyond 1 year were also not significantly different between the 2 groups (0.07% versus 0.2%; P=0.32 and 3.3% versus 2.7%; P=0.39, respectively; Table 3 ; Figure 4 ). The cumulative incidence of any coronary revascularization was significantly higher in the BP-BES group than in the DP-EES group (Table 3) .
In the subgroup analysis, the cumulative incidences of death/MI were not significantly different between the BP-BES and the DP-EES groups in any prespecified subgroups. There was no interaction between the subgroup factors and the effect of BP-BES relative to DP-EES for death/ MI ( Figure 5 ).
Discussion
The main finding of this study was that the safety and efficacy outcomes of BP-BES remained comparable with those of DP-EES through 3 year after stent implantation.
Network meta-analyses have suggested that BP DES had an excess risk for ST or MI compared with second-generation DP-EES. [16] [17] [18] Furthermore, one of the above studies by Bangalore et al 16 incorporating 106 427 patients suggested that BP DES were inferior to second-generation DP-EES for mortality beyond 1 year. However, no head-to-head trial of BP-BES and DP-EES reporting the clinical outcomes beyond 1 year after stent implantation had been included in the metaanalysis. The current largest head-to-head trial of BP-BES and DP-EES revealed that the cumulative 3-year incidence of the safety end point (death/MI) in the BP-BES group was not different from that in the DP-EES group. The efficacy outcome (TLR) of BP-BES was also comparable with that of DP-EES at 3 years. Furthermore, the risk of BP-BES for the late adverse events including death, MI, ST, and TLR between 1 and 3 years was not significantly different from that of DP-EES. Therefore, there was no apparent signal suggesting either improvement or impairment of clinical outcomes with BP-BES compared with DP-EES. Both BP and biocompatible DP could be effective alternatives as the drug release technology from the metallic stent platform. Longer term follow-up might be required to demonstrate the potential benefits of BP DES relative to biocompatible DP DES.
The rates for primary safety and efficacy end point in this trial were lower than expected, which were estimated from those in the j-Cypher registry enrolling patients from 2004 to 2006.
14 A trend toward less events in DES trial has also been seen in most recently published trial. 19 This could be because of improvements in medical treatment during and after the procedure, such as statins and antiplatelet therapy, and better PCI techniques such as optimal apposition using Some limitations must be considered when interpreting our results. First, 3-year follow-up might be insufficient to compare the long-term outcome between BP-BES and DP-EES. The advantage of polymer degradation in the vessel wall could emerge with longer term follow-up. Second, patients participating in the current trial were not fully monitored and, therefore, underreporting of the adverse events, ST in particular, could be possible. However, angiograms in patients with TVR were rigorously evaluated for the presence of thrombus in the angiographic core laboratory, and adjudication of death and MI events was conducted carefully to evaluate the possibility of ST. Third, despite the allcomer design of our trial, there was a high rate of stable patients, which may reflect a selection bias. Patients with acute MI or cardiogenic shock could have been excluded because of difficulties in obtaining informed consent in these settings. This may explain our low event rate compared with previous trials and registries. Finally, this study did not have adequate power to evaluate the low frequency event such as ST, even if this is the largest trial comparing BP-BES with DP-EES. The longer term follow-up of this study would provide important data for such rare but relevant outcomes.
Conclusions
The safety and efficacy outcomes of BP-BES remained comparable with those of DP-EES through 3 years and beyond 1 year after stent implantation. There was no apparent signal suggesting either improvement or impairment of clinical outcomes with BP-BES compared with DP-EES.
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Supplementary Appendix Supplementary Methods
Study Procedures
Biodegradable polymer Biolimus-eluting stent (BP-BES) was available in diameters of 2.50, 2.75, 3.00, and 3.50 mm with each available in lengths of 8, 14, 18, 24 and 28mm. Durable polymer Everolimus-eluting stent (DP-EES) was available in diameters of 2.50, 2.75, 3.00, and 3.50 mm with each available in lengths of 8, 12, 15, 23, and 28mm. Stent implantation procedures were performed according to standard techniques. Use of stents other than the assigned study stent was not allowed unless the delivery of assigned stent was unsuccessful, in which case crossover to another device including the comparator study stent was permitted. Use of the same assigned study stents was recommended in the subsequent scheduled staged percutaneous coronary intervention (PCI) procedures and in the unplanned PCI procedures during follow-up.
Follow-up information at 3-year was obtained by either hospital visit or telephone contact with the patient and/or the referring physician. Electrocardiograms (ECG) and cardiac biomarkers (creatinine kinase (CK) MB fraction and troponins) were to be evaluated before and after the index procedure and at time of suspected ischemic events. Evaluation of ECG and cardiac biomarkers after the procedure were conducted either on the next morning or at the time of hospital discharge, which came earlier.
Definitions of endpoints
Target-lesion revascularization (TLR) was defined as either PCI or coronary artery bypass grafting due to restenosis or thrombosis of the target lesion that included the proximal and distal edge segments as well as the ostium of the side branches. A TLR was considered clinically indicated if angiography during follow-up showed a diameter stenosis greater than or equal to 50 percent (core laboratory quantitative coronary angiographic assessment) and if one of the following occurred: (1) a positive history of recurrent angina pectoris, presumably related to the target vessel; (2) objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel; (3) abnormal results of any invasive functional diagnostic test (e.g. fractional flow reserve); (4) a target lesion revascularization with a diameter stenosis greater than 70% even in the absence of the above-mentioned ischemic signs or symptoms.
1 Scheduled staged PCI procedures declared during the index hospitalization were not included in any coronary revascularization during follow-up.
Death was regarded as cardiac in origin unless obvious non-cardiac causes could be identified. Any death during the index hospitalization for the randomized PCI procedure was regarded as cardiac death. Sudden death was defined as unexplained death in previously stable patients. Myocardial infarction (MI) and stent thrombosis were defined according to the Academic Research Consortium definitions. 2 Procedure-related MI was regarded as present with CK MB fraction >=3 times upper limit of normal after PCI procedure or total CK >=3 times upper limit of normal in the absence of CK MB measurement. Stroke during follow-up was defined as ischemic or hemorrhagic stroke requiring hospitalization with symptoms lasting >24 hours. Hospitalization for heart failure was defined as hospitalization due to worsening heart failure requiring intravenous drug therapy. Bleeding was defined according to the Thrombolysis in Myocardial Infarction (TIMI) classification and the Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded coronary arteries (GUSTO) classification. [3] [4] A device-oriented composite included cardiac death, target-vessel MI, and TLR, while a patient-oriented composite included all-cause death, MI, and any repeat coronary revascularization. 5 Target-lesion failure was defined as the composite of cardiac death, target-vessel MI, or ischemia-driven TLR, while target-vessel failure was defined as the composite of cardiac death, MI, or ischemia-driven target-vessel revascularization (TVR). 6 Major adverse cardiac events were defined as the composite of cardiac death, MI, or ischemia-driven TLR. 6 Acute device success was defined to be achieved when all the study stents attempted were successfully deployed in a given lesion with residual diameter stenosis <50%. Duration of the index procedure was measured by the time interval between insertion and removal of the guiding catheter. Procedure success on a patient level was defined as successful dilatation of at least one target-lesion with residual diameter stenosis <50% without any major in-hospital complications including death, MI, or stroke.
Angiographic analysis
Baseline and post-procedure angiograms were assessed in all patients whose angiograms were available for analysis in the core laboratory. Follow-up angiograms were qualitatively and quantitatively analyzed in patients enrolled in the angiographic sub-study and in patients with TVR during follow-up. According to the previous studies, angiograms obtained within 14 days after the index PCI procedure were excluded from the angiographic analysis. 1 The target segment was defined as the entire segment involving the implanted stent and the 5-mm proximal and distal edges adjacent to the stent. A segment to be treated with multiple overlapping stents was regarded as a single target segment. In addition to the standard angiographic parameters, SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) score was also evaluated. 
